Surgical treatment of head and neck chondrosarcomas

Obeso, Sergio; Llorente, José Luís; Díaz-Molina, Juan Pablo; Sánchez-Fernández, Rafael; Rodrigo, Juan P.; Suárez, Carlos

doi:10.1016/s2173-5735(10)70047-8

Cited by 14 publications

(16 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The primary site was most commonly the cricoid in 75% of cases, followed by the thyroid cartilage in 20%, and epiglottis or arytenoids in 5% [1]. Laryngeal chondrosarcomas appear around the age of 60 to 70 years with a clear predominance in males [1][2][3][4][5], as in our patient.…”

Section: Discussionsupporting

confidence: 58%

“…The standard treatment of laryngeal chondrosarcoma is mainly based on surgical excision [5,6,8]. Partial laryngectomy, preserving laryngeal function, is preferable when tumor location and size allow oncologic control.…”

Section: Resultsmentioning

confidence: 99%

“…Chondrosarcomas were classically considered as radioresistant tumors [4,5,9]. But recent studies [5] have shown radiotherapy effectiveness, particularly in tumors where negative margins resection cannot be obtained. Radiotherapy is reserved for high-grade lesions, lymph node involvement, positive margins resection or local recurrence [5].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Chondrosarcoma of the thyroid cartilage: a rare laryngeal malignancy

Ca¹,

Loum²,

Tb³

et al. 2017

Otorhinolaryngol Head Neck Sur

View full text Add to dashboard Cite

Laryngeal chondrosarcoma is a rare malignant tumor that arises from the cartilaginous structures of the larynx. It is a slow-growing neoplasm with high tendency to locoregional recurrence after treatment. Surgery is the primary treatment. Prognosis depends on histological differentiation degree and quality of surgical excision which can be very mutilating. Distant metastatis can occur in cases of histological high-grade tumors. From a new observation and a review of the literature, we discuss the clinical characteristics, therapeutic modalities and patient outcomes.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Chondrosarcoma of the thyroid cartilage: a rare laryngeal malignancy

Ca¹,

Loum²,

Tb³

et al. 2017

Otorhinolaryngol Head Neck Sur

View full text Add to dashboard Cite

show abstract

“…Vaz-Guimaraes et al (46) 2004 Feuvret et al (32) 1996 Obeso et al (45) 1977 Cho et al (35) 1991 Prado et al (41) 1953-2002 11-70yrs; 9:7 Retrospective study; maxilla (7), ethmoid Gadwal et al (29) 1970-1997 Rosenberg et al (5) 1978-1997 Saito et al (23) 1927-1992 1.5-88yrs; 27:29 Retrospective study; maxilla/maxillary sinus (25), nasal septum/ ethmoid/sphenoid (23), mandible (6), nasal tip 256; Grade 1 (43), Grade 2 (13) Sx (46), CRT (2), RT (1), biopsy only (2), unknown treatment (5) LR (14), uncontrolled LR (9); Survival 5yrs 80.7%, 10yrs 65.3%, 15yrs 56%…”

Section: Review Of the Literaturementioning

confidence: 99%

Management of sinonasal and skull base nonmesenchymal chondrosarcoma, a narrative review

Ferguson¹,

Lund²,

Howard³

et al. 2018

RHINOL

View full text Add to dashboard Cite

Background: Chondrosarcoma (CS) is a rare malignant cartilage forming tumor accounting for 6% of skull base neoplasia. CS often presents insidiously, it almost never metastasizes but it has an indolent progressive course leading to significant morbidity and mortality due to invasion of the clivus and central skull base. This study performed a review of the management of CS. Methods: A review of English language literature identified 20 studies to which we added a case series from one institution. Results: Total number of patients included was 734. Main treatment modality was surgery performed in combination with postoperative radiotherapy (64.0%) or surgery alone (30.4%). The majority of patients recorded were either alive and well (68.1%) or alive with disease (16.6%) with 15.3% dead of disease. Conclusions: On present evidence, surgery should form the primary treatment with a goal of complete resection. Inaccessible recurrences or high grade tumors are candidates for proton beam radiotherapy following surgery.

show abstract

“…[17] Chemotherapy is used for palliation or as adjuvant therapy in cases of aggressive behavior or potential metastases for maximizing local control and treating the potential of micrometastatic disease. [17,18] Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role. Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial.…”

Section: Published By Sciedu Pressmentioning

confidence: 99%